medigraphic.com

2015, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2015; 53 (1)

Clonality lymphoid study through rearrangement analysis of antigen receptor

Villamizar-Rivera N, Olaya N

Language: Spanish
References: 35
Page: 56-65
PDF size: 267.91 Kb.


ABSTRACT

As a rule, malignant lymphoid proliferations are clonal. While most of the time the biological potential can be established through routine pathologic examination and auxiliary techniques, some cases are diffi cult to classify. Moreover, there are situations in which there are dominant clones whose analysis are important, such as occur in autoimmune diseases and immunodefi ciency. This paper presents in an understandable way the main techniques for the study of clonality in lymphoid lesions, i.e. the analysis of rearrangements of antigen receptor genes by multiplex polymerase chain reaction (PCR) based tests.


REFERENCES

  1. MelGreaves, Carlo C Marley. Clonalevolution in cancer. Nature 2012;481(10762):306-313.

  2. Swerdlow SH, Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Vardiman, J.W. WHO Classifi cation of Tumours of Haematopoietic and Lym phoidTissues, FourthEdition. Lyon, France: WHO 2008.

  3. Elaine S. Jaffe NLH, James Vardiman, Elias Campo, Daniel MD Arber. Hematopathology. FirstEdition. Maryland, USA: El sevier 2010.

  4. Van Dongen JJM, Langerak AW, Brüggemann M, Evans PAS, Hummel M, Lavender Fl, et al. Design and standarization of PCR primers and protocolsfordetection of clonalimmunoglobulin and T-cell receptor gene recombinations in suspectlymphoproliferations: Report of BIOMED-2 ConcertedAction BMH4-CT98-3936. Leukemia 2003;17:2257-2317.

  5. Perfetti V, Brunetti L, Biagi F, Ciccocioppo R, Bianchi PI, Corazza GR. TCRβ clonalityimprovesdiagnosticyield of TCRγclonality in refractoryceliacdisease. J ClinGastroenterol 2012;46(8):675-679.

  6. Sirsath NT, Channaviriappa L, Nagendrappa LK, Dasappa L, Sathyanarayanan V, Setty GB. Human immunodefi ciency virus - associatedlymphomas: a neglecteddomain. N Am J MedSci 2013;5(7):432-437.

  7. Abbas AK. INMUNOLOGÍA celular y molecular. NinthEdition. San Francisco, USA: El Sevier; 2009.

  8. Giallourakis CC, Franklin A, Guo C, Cheng HL, Yoon HS, Gallagher M, et al. ElementsbetweentheIgH variable (V) and diversity (D) clustersinfl uenceantisensetranscription and lineagespecifi cV(D)J recombination. ProcNatlAcadSci U S A 2010;107(51):22207-22212.

  9. Deriano L, Chaumeil J, Coussen M, Multani A, Chou YF, Alekseyenko AV, et al. The RAG2 C-terminussuppressesgenomicinstability and lymphomagenesis. Nature. 2011;471(7336):119-123.

  10. Knowles II DM, Neri A, Pelicci PG, Burke JS, Wu A, Winberg CD, et al. Immunoglobulin and T-cellreceptorB- chain gene rearrangementanalysys of Hodgkin’sDisease: Implicationsforloneagedetermination and differential diagnosis. ProcNatlAcadSci U S A 1986;83(1):7942-7946.

  11. EuroClonality. EuroClonality 2013 (consultado 2013 Oct 10). Disponible en http://www.euroclonality.org/.

  12. Invivoscribe. Invivoscribe | Personalized Molecular Medicine 20 (consultado 2013 Oct 28). Disponible en http://www.invivoscribe.com/.

  13. Melotti CZ, Carriel MF, Sotto MN, Diss T, Sanches JA. PolymeraseChainReaction-BasedClonality- Analysis of Cutaneous B-CellLymphoproliferative- Processes. Clinics 2010;65(1):53-60.

  14. Susan Harris, M Bruggemann, P. J. T. A Groenen, E. Shuuring, A. W. Langerak, E. Hodges. Clonalityanalysis in lymphoproliferativediseaseusingthe BIOMED-2 multiplex PCR protocols: experiencefromtheEuroClonalitygroup EQA scheme. Journal of Hematopathology 2012;5(1-2):91-98.

  15. Van den Beemd R, Boor PP, Van Lochem EG, Hop WC, Langerak AW, Wolvers-Tettero IL, et al. Flowcytometricanalysis of theVbetarepertoire in healthycontrols. Cytometry 2000;40(4):336-345.

  16. Kalina T, Flores-Montero J, Van der Velden VH, Martin- Ayuso M, Böttcher S, Ritgen M, et al; EuroFlow- Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlowstandardization of fl owcytometerinstrumentsettings and immunophenotypingprotocols. Leukemia 2012;26(9):1986-2010.

  17. J. Han van Krieken, JoseCabecadas, Patricia J, Groenen TA. Clonalitytesting: tamworkbypathologist and molecular biologist. Journal of Hematopathology 2012;5(1-2):3-5.

  18. Irina Bonzheim, FlorianFrölich, Patrick Adam, Sema Colak, Gisela Metzler, FalkoFend, et al. A comparativeanalysis of protocolsfordetection of T cellclonality in formalin-fi xed, paraffi n-embeddestissue- implicationsforpractical use. Journal of Hematopathology 2012;5(1-2):7-16.

  19. Paireder S, Werner B, Bailer J, Werther W, Schmid E, Patzak B, et al. Comparison of protocolsfor DNA extractionfromlong-termpreservedformalinfi xedtissues. Anal Biochem 2013;2(439):452-460.

  20. Van Krieken JH, Langerak AW, Macintyre EA, Kneba M, Hodges E, Sanz RG, et al. Improvedreliability of lymphomadiagnosticsvia PCR-basedclonalitytesting: report of the BIOMED-2 ConcertedAction BHM4-CT98-3936. Leukemia 2007;21(2):201-206.

  21. Medeiros LJ, Carr J. Overview of the role of molecular methods in the diagnosis of malignantlymphomas. ArchPatholLabMed. 1999;123(12):1189-1207.

  22. K. M. Hebeda, M.C. Van Altena, P. Rombout, J.H.J. M. Van Krieken, P. J. T. A. Groenen. PCR clonalitydetection in Hodgkinlymphoma. Jornal of Hematopathol 2013:34-41.

  23. Beaufi ls N, Ben Lassoued A, Essaydi A, Dales JP, Formisano-Tréziny C, Bonnet N, et al. Analysis of T-cell receptor-γ gene rearrangementsusingheteroduplexanalysisbyhigh- resolutionmicrocapillaryelectrophoresis. Leuk Res 2012;36(9):1119-1123.

  24. Evans PA, Pott Ch, Groenen PJ, Salles G, Davi F, Berger F, et al. Signifi cantlyimproved PCR-basedclonalitytesting in B-cellmalignanciesby use of multipleimmunoglobulin gene targets. Report of the BIOMED-2 ConcertedAction BHM4-CT98-3936. Leukemia 2007;21(2):207-214.

  25. Langerak AW, Groenen PJ, Brüggemann M, Beldjord K, Bellan C, Bonello L, et al. EuroClonality/BIOMED-2 guidelinesforinterpretation and reporting of Ig/TCR clonalitytesting in suspectedlymphoproliferations. Leukemia 2012;26(10):2159-2171.

  26. Ortiz YM, Arias L, Alvarez CM, García LF. Memoryphenotype and polyfunctional T cells in kidneytransplantpatients. TransplImmunol 2013;28(3):127-137.

  27. Pińa-Oviedo S, Fend F, Kramer M, Fournier F, Farca A, Ortiz-Hidalgo C. Diagnosis of earlygastric marginal zonelymphoma (MALT lymphoma) in endoscopicbiopsies. Report of a case thatdemonstratestheutility of immunohistochemistry and the molecular analysis. RevGastroenterolMex 2008;73(3):172-176.

  28. Stefanoff CG, Hassan R, Gonzalez AC, Andrade LA, Tabak DG, Romano S, et al. Laboratorystrategiesforeffi cienthandling of paraffi n-embeddedtissuesfor molecular detection of clonality in non-hodgkinlymphomas. Diagn Mol Pathol 2003;12(2):79-87.

  29. Andrea Bosaleh, Valeria Denninghoff, Alejandro García, Carla Rescia, Alejandra Avagnina, Boris Elsner. Rearreglos de genes de cadenas pesadas de las inmunoglobulinas en las gammapatias monoclonales. Scielo 2005;65(1)229-225.

  30. Quesnel B, Preudhomme C. Residual disease: thehematologist’spoint of view. Bull Cancer. 2001;88(6):571-575.

  31. Garand R, Beldjord K, Cavé H, Fossat C, Arnoux I, Asnafi V, et al. Flowcytometry and IG/TCR quantitative PCR forminimal residual diseasequantifi cation in acutelymphoblasticleukemia: a French multicenterprospectivestudyonbehalf of the FRALLE, EORTC and GRAALL. Leukemia 2013;27(2):370-376.

  32. Van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognosticvalue of minimal residual disease in acutelymphoblasticleukaemia in childhood. Lancet. 1998;352(9142):1731-1738.

  33. Cavé H, Van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinicalsignifi cance of minimal residual disease in childhoodacutelymphoblasticleukemia. EuropeanOrganizationforResearch and Treatment of Cancer--ChildhoodLeukemiaCooperativeGroup. N Engl J Med 1998;339(9):591-598.

  34. Weng XQ, Shen Y, Sheng Y, Chen B, Wang JH, Li JM. Prognosticsignifi cance of monitoringleukemiaassociatedimmuniphenotypesbyeight- color fl owcytometry in adult B-acutelymphoblasticleukemia. BloodCancer J 2013;16(3):133-143.

  35. Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, et al. Estandardized MRD quantifi cation in European ALL trials: proceedings of theSecond International Symposiumon MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010;24(3):521-535




2020     |     www.medigraphic.com